A study to evaluate the effect of CYP2C19 and POR genotypes on the pharmacokinetic parameters of clobazam in Japanese patients with epilepsy

Trial Profile

A study to evaluate the effect of CYP2C19 and POR genotypes on the pharmacokinetic parameters of clobazam in Japanese patients with epilepsy

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Clobazam (Primary)
  • Indications Epilepsy
  • Focus Pharmacokinetics
  • Most Recent Events

    • 18 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top